Evidence map›Paper›PMID 29097929›Full record

ArticleContrast media & molecular imaging2017

Evaluation of Peripheral Zone Prostate Cancer Aggressiveness Using the Ratio of Diffusion Tensor Imaging Measures.

Aslihan Onay, Gokhan Ertas, Metin Vural, Omer Acar, Yesim Saglican, Bilgen Coskun, Sergin Akpek

Abstract read
In one paragraph

Article in Contrast media & molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Clinical application and progress of quantitative functional magnetic resonance imaging in prostate cancer.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2021
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aslihan OnayDepartment of Radiology, Koç University School of Medicine, Istanbul, Turkey.
Gokhan ErtasDepartment of Biomedical Engineering, Yeditepe University, Istanbul, Turkey.ORCID 0000-0002-3331-9152
Metin VuralDepartment of Radiology, VKF American Hospital, Istanbul, Turkey.ORCID 0000-0003-1341-6120
Omer AcarDepartment of Urology, Koç University School of Medicine, Istanbul, Turkey.
Yesim SaglicanDepartment of Pathology, Acibadem University School of Medicine, Istanbul, Turkey.
Bilgen CoskunDepartment of Radiology, VKF American Hospital, Istanbul, Turkey.
Sergin AkpekDepartment of Radiology, Koç University School of Medicine, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To evaluate the aggressiveness of peripheral zone prostate cancer by correlating the Gleason score (GS) with the ratio of the diffusion tensor imaging (DTI) measures. Materials and Methods: Forty-two peripheral zone prostate tumors were imaged using DTI. Regions of interest focusing on the center of tumor foci and noncancerous tissue were used to extract statistical measures of mean diffusivity (MD) and fractional anisotroy (FA). Measure ratio was calculated by dividing tumor measure by noncancerous tissue measure. Results: Strong correlations are observable between GS and MD measures while weak correlations are present between GS and FA measures. Minimum tumor MD (MD Conclusion: Ratios of MD measures can be used in evaluation of peripheral zone prostate cancer aggressiveness; however tumor MD measures alone perform similarly.

Indexed as

AnisotropyDiffusion Tensor ImagingHumansMaleNeoplasm GradingProstatic Neoplasms

Identifiers

PMID29097929
PMCPMC5635474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.